Oncology ontology prototype

Read left to right: each synthetic patient has a diagnosis, which links to the labs that monitor it and the drugs that treat it. The links are hand-curated for this demonstration and are not clinical guidance.

Patient (synthetic)

SYN-001

58 F

SYN-002

67 M

SYN-003

61 M

SYN-004

72 F

SYN-005

49 M

Diagnosis (ICD-10-CM)

Breast cancer, female

C50.919

Lung cancer

C34.90

Colon cancer

C18.9

Prostate cancer

C61

Malignant brain tumor

C71.9

Chronic myeloid leukemia

C92.10

Lab (LOINC)

ER status

40556-3

PR status

40557-1

PSA, serum

2857-1

White blood cell count

6690-2

Hemoglobin

718-7

Drug (RxNorm)

Selective estrogen receptor modulator

tamoxifen

Nolvadex

Aromatase inhibitor

anastrozole

Arimidex

letrozole

Femara

CYP17 inhibitor

abiraterone

Zytiga

Tyrosine kinase inhibitor

imatinib

Gleevec

lapatinib

Tykerb

erlotinib

Tarceva

Antimetabolite

capecitabine

Xeloda

methotrexate

Trexall

Alkylating agent

temozolomide

Temodar

Synthetic patient cohort

Five made-up patients for demonstration only. They are not real people and contain no real patient data.

PatientDiagnosis (ICD-10-CM)Lab results (LOINC)Drug

SYN-001

58, female

Breast cancer, female

C50.919

  • ER status: Positive · 40556-3
  • PR status: Positive · 40557-1
  • Hemoglobin: 12.9 g/dL · 718-7
  • anastrozole 1 mg (Arimidex)

SYN-002

67, male

Prostate cancer

C61

  • PSA, serum: 12.4 ng/mL · 2857-1
  • Hemoglobin: 13.6 g/dL · 718-7
  • abiraterone 250 mg (Zytiga)

SYN-003

61, male

Lung cancer

C34.90

  • Hemoglobin: 11.2 g/dL · 718-7
  • erlotinib 150 mg (Tarceva)

SYN-004

72, female

Colon cancer

C18.9

  • Hemoglobin: 10.8 g/dL · 718-7
  • capecitabine 500 mg (Xeloda)

SYN-005

49, male

Chronic myeloid leukemia

C92.10

  • White blood cell count: 96.5 10*9/L · 6690-2
  • Hemoglobin: 10.1 g/dL · 718-7
  • imatinib 400 mg (Gleevec)